Alpha 2.0
Login Register
» Articles » PMID: 19536122

Addressing the Challenges of the Clinical Application of Pharmacogenetic Testing

Overview
Journal Clin Pharmacol Ther
Publisher Wiley
Specialty Pharmacology
Date 2009 Jun 19
PMID 19536122
Citations 12
Authors
O N Ikediobi
J Shin
R L Nussbaum
K A Phillips
J M Walsh
U Ladabaum
D Marshall
Affiliations
Soon will be listed here.
Abstract

Pharmacogenomics aims to use molecular genetic markers to predict treatment outcome. Indeed, within the past decade there has been a rapid emergence of pharmacogenetic tests to aid clinicians in predicting efficacy or toxicity for some drugs. Despite this major advance in therapeutic drug management, there remain challenges to the appropriate use of pharmacogenetic tests. We discuss UGT1A1 pharmacogenetic testing to illustrate the knowledge gaps impeding widespread use of pharmacogenetic tests in the clinical setting.

Citing Articles

Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice.

Tafazoli A, Guchelaar H, Miltyk W, Kretowski A, Swen J Front Pharmacol. 2021; 12:693453.

PMID: 34512329 PMC: 8424415. DOI: 10.3389/fphar.2021.693453.

Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.

Oates J, Lopez D Int J Biomed Investig. 2020; 1(2).

PMID: 32467882 PMC: 7255432. DOI: 10.31531/2581-4745.1000111.

The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?.

Dias M, Sorich M, Rowland A, Wiese M, McKinnon R Pharm Res. 2017; 34(8):1544-1550.

PMID: 28236061 DOI: 10.1007/s11095-017-2128-0.

Challenges of development and implementation of point of care pharmacogenetic testing.

Haga S Expert Rev Mol Diagn. 2016; 16(9):949-60.

PMID: 27402403 PMC: 6709578. DOI: 10.1080/14737159.2016.1211934.

Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.

Haga S, Allen LaPointe N, Cho A, Reed S, Mills R, Moaddeb J Pharmacogenomics. 2014; 15(13):1677-86.

PMID: 25410893 PMC: 4280849. DOI: 10.2217/pgs.14.109.

References
1.
Scheuner M, Sieverding P, Shekelle P . Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA. 2008; 299(11):1320-34. DOI: 10.1001/jama.299.11.1320. View
2.
Hoskins J, Goldberg R, Qu P, Ibrahim J, McLeod H . UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007; 99(17):1290-5. DOI: 10.1093/jnci/djm115. View
3.
Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H . Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2001; 60(24):6921-6. View
4.
. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?. Genet Med. 2009; 11(1):15-20. PMC: 2743610. DOI: 10.1097/GIM.0b013e31818efd9d. View
5.
Strassburg C . Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics. 2008; 9(6):703-15. DOI: 10.2217/14622416.9.6.703. View